Virax Biolabs Group Limited

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/01/2026 GMT			5-day change	1st Jan Change
0.3140 ^USD	-5.76%		-14.67%	-9.20%

12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI

HC Wainwright Initiates Virax Biolabs at Buy With $3 Price Target

Published on 03/31/2025 at 01:52 pm BST - Modified on 03/31/2025 at 01:53 pm BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Virax Biolabs Group Limited

12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune?? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	CI
26/08/25	Virax Biolabs to Collaborate With Emory University on Long COVID Clinical Studies	MT
26/08/25	Virax Biolabs partners with Emory University on ViraxImmune(TM) clinical studies	RE
26/08/25	Virax Biolabs Group Limited Partners with Emory University on ViraxImmune Clinical Studies	CI
29/07/25	Virax Biolabs Group Limited Announces Board Changes	CI
29/07/25	Virax Biolabs Group appoints Iain Miller, Ph.D. as independent director to accelerate commercial strategy	RE
18/07/25	Virax Biolabs Gets Nasdaq Non-Compliance Notice	MT
02/07/25	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI
13/06/25	Virax Biolabs Group CFO Jason Davis To Resign	RE
31/03/25	HC Wainwright Initiates Virax Biolabs at Buy With $3 Price Target	MT
18/03/25	Virax Biolabs Group Limited Enrolls First Patients in Clinical Study Assessing T Cell Dysfunction in Post-Acute Infection Syndromes	CI
13/03/25	Virax Biolabs Group Limited Presents Data on T-Cell Dysfunction in Post-Acute Infection Syndromes at the 19th World Immune Regulation Meeting	CI
13/01/25	Cosmos Health to Distribute Virax Avian Influenza PCR Kits in Europe, GCC Countries	MT
13/01/25	Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries	CI
17/12/24	Virax Biolabs Group Limited Announces New Distribution Agreements	CI
17/12/24	Virax Biolabs Initiates UK Clinical Study for ViraxImmune? Platform to Detect T-Cell Dysfunction in Post-Acute Infectious Syndrome Patients	CI
20/11/24	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2024	CI
23/10/24	Top Midday Gainers	MT
23/10/24	Wall Street Set to Open Lower Wednesday as Investors Await Economic Data	MT
23/10/24	Virax Biolabs Group Limited Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland	CI
23/09/24	Cosmos Health Signs Deal to Distribute Virax Biolabs' Mpox PCR Detection Kits in India	MT
23/09/24	Cosmos Health Inc. Expands Global Presence into India Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits	CI
16/09/24	Virax Biolabs Extends Exclusive Distribution Deal for Mpox Virus Test Kits; Shares Rise Pre-Bell	MT

Chart Virax Biolabs Group Limited

Duration

Period

VRAX: Dynamic Chart

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Employees

Sector

Biotechnology & Medical Research

More about the company